Skip to main content
. 2022 Apr 19;38(2):414–424. doi: 10.1093/ndt/gfac150

Table 4.

Patients who remained withdrawn from eculizumab treatment at the end of the observation period

Patient Agea Sex Number of TMA episodes prior to eculizumab Family history of aHUS Genetic variantb/antibody Total days of eculizumab treatment Recurrence of aHUS Days after discontinuation Treatment at last observation
1 10 years F 1 Y CFHR1 p.Asp35fsX36, anti-CFH antibody 1010 N 337
2 10 years M 1 N CFHR3 exon 6 deletion, anti-CFH antibody 105 N 1681 PSL, CsA
3 17 years M 2 Y C3 p.Ile1157Thr 424 N 308
4 17 years M 3 N MCP p.Asp170Met FsX9 (Homo) 1 N 408
5 5 years M 1 N Not examined, anti-CFH antibody 357 N 1438
6 16 years F 1 N Not examined 213 N 754
7 16 years M 1 N Not examined (positive for haemolytic assay) 575 N 126 Peritoneal dialysis
8 7 years M 1 N CFHR1-CFHR3 deletion, anti-CFH antibody 595 N 371
9 11 years F 1 N Not identified, anti-CFH antibody 603 N 128
10 7 months F 1 N Not identified 8 N 727 PSL
11 9 months M 1 N C3 p.Ser179Pro, CFH p.Hus402Tyr (homo), p.Glu936Asp (homo) 327 N 465
12 4 years M 1 N CFHR1-CFHR3 deletion, anti-CFH antibody 385 N 708 PSL, MMF
13 6 years F 1 N CFH p.His402Tyr, p.Glu936Asp, MCP p.Thr163Ile 29 N 326

F, female; M, male; Y, yes; N, no; PSL, prednisolone; CsA, cyclosporin.

aAge at first administration. bThe information on homozygosity or heterozygosity of the genetic variant is not available if there is no description in this table.